Chemotherapy in Pancreatic Cancer: A Systematic Review.

ABSTRACT:

Background and aim

Pancreatic cancer is one of the most fatal cancers. Cytotoxic chemotherapy remains the mainstream treatment for unresectable pancreatic cancer. This systematic review evaluated and compared the overall survival (OS) and progression-free survival (PFS) outcomes obtained from recent phase 2 and 3 clinical trials of pancreatic cancer chemotherapy.

Materials and methods

Thirty-two studies were included and compared based on chemotherapy agents or combinations used. Additionally, outcomes of first-line versus second-line chemotherapy in pancreatic cancer were compared.

Results

In studies that investigated the treatments in adjuvant settings, the highest OS reported was for S-1 in patients, who received prior surgical resection (46.5 months). In neoadjuva

SUBMITTER: Hajatdoost L 

PROVIDER: S-EPMC6122094 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature